AMYLIN, HUMAN CAS NO (122384-88-7) available for sale

1. Introduction to Human Amylin (122384-88-7):

Human Amylin, also known as islet amyloid polypeptide (IAPP), is a peptide hormone produced by pancreatic beta cells. It plays a crucial role in glucose homeostasis and appetite regulation, working in conjunction with insulin to control blood sugar levels. With its multifaceted physiological functions, human amylin is implicated in various metabolic disorders, including diabetes mellitus.

2. Chemical Composition and Molecular Structure:

Human Amylin is a 37-amino acid peptide hormone with a molecular weight of approximately 3.9 kDa. It is synthesized as a precursor protein, proamylin, which undergoes post-translational processing to generate the mature hormone. The primary sequence of human amylin includes an amidated C-terminus and a disulfide bond between cysteine residues at positions 2 and 7, which confer structural stability.

3. Physiological Functions:

Human Amylin functions as a regulator of glucose metabolism and appetite, complementing the actions of insulin to maintain euglycemia and satiety. It inhibits glucagon secretion, delays gastric emptying, and suppresses appetite through central and peripheral mechanisms. By modulating food intake and glucose utilization, human amylin contributes to energy balance and metabolic homeostasis.

4. Role in Glucose Homeostasis:

One of the key functions of human amylin is its ability to regulate postprandial glucose levels by slowing down the rate of gastric emptying and inhibiting glucagon secretion from pancreatic alpha cells. This coordinated action with insulin helps prevent postprandial hyperglycemia and contributes to overall glycemic control.

5. Appetite Regulation:

Human amylin acts as a satiety hormone, signaling to the brain to reduce food intake and promote feelings of fullness and satisfaction after meals. By interacting with receptors in the hypothalamus and brainstem, it modulates appetite and food-seeking behaviors, thereby influencing energy intake and body weight regulation.

6. Implications in Diabetes Mellitus:

In diabetes mellitus, dysregulation of human amylin secretion and aggregation can contribute to the pathogenesis of the disease. In type 1 diabetes, reduced insulin and amylin production leads to impaired glucose metabolism and hyperglycemia. In type 2 diabetes, amylin oligomerization and deposition contribute to the formation of pancreatic amyloid plaques, which may exacerbate beta cell dysfunction and insulin resistance.

7. Therapeutic Potential:

Given its role in glucose homeostasis and appetite regulation, human amylin has therapeutic potential for the management of diabetes and obesity. Synthetic analogs of amylin, such as pramlintide, have been developed as adjunctive therapies to insulin in type 1 and type 2 diabetes, offering benefits in glycemic control and weight management.

8. Challenges and Limitations:

Despite its therapeutic promise, the clinical utility of human amylin and its analogs is limited by challenges such as subcutaneous administration, dosing frequency, and potential side effects such as hypoglycemia and gastrointestinal disturbances. Further research is needed to optimize amylin-based therapies and explore novel delivery systems for enhanced efficacy and patient compliance.

9. Future Directions and Research Opportunities:

Continued research into the physiological roles, signaling pathways, and therapeutic applications of human amylin holds promise for advancing our understanding of metabolic regulation and developing innovative treatments for diabetes and related metabolic disorders. Exploration of amylin receptor agonists, combination therapies, and targeted delivery approaches may lead to improved outcomes and quality of life for patients with diabetes and obesity.

10. Conclusion:

Human Amylin is a multifunctional peptide hormone with significant implications in glucose homeostasis, appetite regulation, and metabolic health. Despite its complexities and challenges, human amylin remains a valuable target for therapeutic intervention in diabetes and obesity, offering opportunities for innovative drug development and personalized treatment strategies aimed at improving patient outcomes and well-being.